Biomarker-Based Prediction of Tyrosine Kinase Inhibitor Cardiotoxicity using Human iPSC-Derived Cardiomyocytes

Presented by Jessica Palmer at the Safety Pharmacology Society Meeting in Barcelona, Spain; September, 2019

Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.